

Supporting Information

Efficient Analysis of Pharmaceutical Drug Substances and Products Using Solid-State NMR CryoProbe

Yong Du¹, Jochem Struppe², Barbara Perrone³, Alia Hassan³ Anna Codina⁴, and Yongchao Su^{1,*}

¹Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, United States

²Bruker Biospin Corporation, Billerica, MA 01821, United States

³Bruker Switzerland, 8117 Faellanden, Switzerland

⁴Bruker UK Ltd., Coventry, CV4 9GH

*Corresponding author: Y.S.: yongchao.su@merck.com

Table S1. Experimental and sample parameters for 1D ^1H - ^{13}C and ^1H - ^{15}N CP spectra of crystalline POSA Form I using the 3.2 mm CryoProbe and a regular 4.0 mm MAS (**Figure 3**). These parameters are used for calculating ^{13}C and ^{15}N signal enhancement factors as described in **Equation 1**.

	S/N		Weight (mg)		B_0 (T)		Number of Scans		Recycle Delay (s)	
	Cryo	Regular	Cryo	Regular	Cryo	Regular	Cryo	Regular	Cryo	Regular
C5	282.9	129.2	62.6	67.4	14.1	9.4	128	2048	5.7	5.7
C50	347.7	139.7								
N21	45.3	21.5					2400	22000	5.7	12.0*
N29	62.0	28.9								




Figure S1. 2D ^{13}C - ^{13}C rINADEQUATE spectrum of crystalline POSA Form I. The 1D ^{13}C projections are displayed on the top and side. Note that the peaks color-labeled in blue result from the spectral folding.